2 results
Approved WMOPending
The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of BMS-986178 administered alone or in combination with nivolumab and/or ipilimumab in…
Approved WMORecruiting
1. To test the hypothesis that an age adapted immunosuppressive regimen targeted at reduced immunosuppression with low calcineurin inhibitor exposure will result in improved outcome in elderly recipients of A: kidneys from older deceased donors (…